Who mentions $CRSP most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $CRSP most — 5 mentions in the past 12 months.

When was $CRSP first mentioned on Surfaced?

The earliest tracked mention of $CRSP in the Surfaced archive was on Oct 22, 2025.

How many voices track $CRSP?

6 FinTwit voices have mentioned $CRSP 13 times in the past 12 months.

What kind of voices mention $CRSP most?

$CRSP is mentioned most by Long Research voices on Surfaced.

$CRSP — FinTwit mentions on Surfaced

Recent mentions

13 mentions

@ftr_investorsJul 17, 2026 · 8:59 AM

Open on X

@adamfeuersteinJul 2, 2026 · 12:54 PM

Read here: A year after distressed buyout, what’s become of Bluebird Bio? CEO David Meek says the company, now called Genetix, is leading in sickle cell gene therapy $VRTX $CRSP $BEAM via @Jasonmmast https://t.co/PJcIWvMOcO

Open on X

@adamfeuersteinJul 2, 2026 · 12:54 PM

A year after distressed buyout, what’s become of Bluebird Bio? (Besides the new name, Genetix) Well... a lot, Genetix CEO David Meek told @Jasonmmast in a swaggering interview this week. Let me summarize Meek's proclamations: Genetix is profitable and on target to dominate the market for sickle cell gene therapies. "We’re the market leaders,” he said. “And our lead is just getting bigger," Meek said. $VRTX $CRSP Casgevy sucks, and the $BEAM effort is lame. “Let’s see if Beam even comes out, right? It’s a ghost right now,” he said. He offered no proof to back up the claims. Read more from Jason's interview with David Meek, link below.

Open on X

@investmentguru_Jul 1, 2026 · 11:38 PM

While AI continues to dominate headlines, Biotechnology is quietly becoming one of the strongest sectors in the market. Top 15 Biotechnology Stocks to Watch: $VRTX – Leader in cystic fibrosis treatments and expanding into gene-editing and rare diseases. $RVMD – Focused on precision oncology targeting RAS-driven cancers. $CRSP – Pioneer in gene-editing with approved and pipeline therapies. $NTLA – Developing in-vivo gene-editing treatments with breakthrough potential. $ABCL – AI-powered antibody discovery platform for drug development. $RXRX – Uses AI and automation to accelerate drug discovery at scale. $BEAM – Specializes in base-editing gene technology for precise DNA correction. $XENE – Focused on neurology and epilepsy-related treatments. $GH – Leader in liquid biopsy cancer diagnostics and early detection. $TWST – Produces synthetic DNA used in genomics and biotech research. $CGON – Developing immunotherapy treatments for bladder cancer and oncology. $DNLI – Focused on neurodegenerative diseases like Alzheimer’s and Parkinson’s. $IMVT – Developing therapies for autoimmune diseases using antibody technology. $ARWR – RNA interference platform targeting genetic and chronic diseases. $KRYS – Commercial-stage gene therapy company focused on rare skin disorders. These names represent the frontier of modern medicine where genetics, AI, and precision therapies are converging. As capital rotates beyond AI infrastructure, biotech is shaping up as one of the most compelling long-term opportunity sectors.

Open on X

@investmentguru_Jun 21, 2026 · 2:24 PM

The Next Trillion-Dollar Wave Isn’t in Semiconductors. It’s in Your Bloodstream. Everyone’s watching chips, NeoCloud, and power. Meanwhile, AI is quietly rewiring healthcare from reactive to predictive — and almost nobody is positioned for it. Healthcare is moving through the same kind of capital cycle we’ve mapped in AI infrastructure: a foundational layer (genomics) enabling a diagnostic layer (AI-read data) enabling a delivery layer (personalized treatment) enabling a behavioral layer (digital therapeutics that keep patients engaged). Four layers, four sets of plays. 1. Gene Therapies — The Foundational Layer This is the “silicon” of biotech: rewrite the underlying code, fix the disease at the source. 2026 has been a genuine inflection point — the FDA has leaned into faster, more flexible review pathways for cell and gene therapies, and the pipeline is converting. •$QURE (uniQure) — surged sharply this month on a major gene therapy advancement; a name riding the regulatory tailwind directly •$RGNX (REGENXBIO) — AAV gene therapy platform with a PDUFA decision already through in February and multiple late-stage pivotal readouts through 2026; partnered with AbbVie on what could be the first gene therapy for a non-rare disease (wet AMD) •$NTLA (Intellia) / $CRSP (CRISPR Therapeutics) / $BEAM (Beam Therapeutics) — the core gene-editing complex; CRSP remains range-bound despite holding the world’s first approved CRISPR therapy, which is exactly the kind of “stuck but structurally important” setup worth tracking 2. AI-Assisted Diagnostics — The Inference Layer This is where AI infrastructure spend actually shows up as patient outcomes. The model: ingest multimodal data (genomic, imaging, clinical), run inference, return an actionable diagnosis faster than a human panel. •$TEM (Tempus AI) — the clearest pure-play. Q1 2026 revenue +36% YoY to $348M, diagnostics revenue +35%, MRD test volume up ~500% YoY, full-year guidance raised to $1.59–1.60B. This is the diagnostics version of a NeoCloud growth curve •$PACB (Pacific Biosciences) — sequencing infrastructure, the “memory layer” underneath every genomic diagnostic •$BFLY (Butterfly Network) — point-of-care imaging, AI-assisted ultrasound, democratizing diagnostic access 3. Precision Medicine — The Targeting Layer Where genomics and diagnostics converge into “right drug, right patient, right time.” •$PRAX (Praxis Precision Medicines) — CNS precision neuroscience, translating genetic epilepsy insights into targeted therapies, multiple readouts ahead in 2026 •$RGNX again earns a mention here — its retinal and Duchenne programs are precision-targeted by genetic subtype, not blanket indications •Watch the AbbVie/Gilead-style partnership pattern — Big Pharma is increasingly outsourcing precision targeting to smaller platform companies rather than building in-house, which is where the asymmetric upside sits 4. Digital Therapeutics — The Engagement Layer The layer that keeps patients adherent and reduces cost-of-care between clinical touchpoints — software as the prescription. •$HIMS (Hims & Hers) — already a long-term holding in the core portfolio; consumer-facing digital health at scale •$GDRX (GoodRx) — Pharma Direct revenue +82% YoY in Q1 2026, a real signal that the direct-to-consumer medication/therapeutics rail is accelerating •$TDOC (Teladoc) — legacy name still worth tracking as the digital-care distribution layer consolidates The framework, simply: Genomics writes the code → AI reads the code → precision medicine targets the code → digital therapeutics keeps you compliant with the fix. Same wave structure as chips → memory → photonics → energy, just running through biology instead of silicon. This sector moves on binary catalysts (PDUFA dates, trial readouts) rather than smooth growth curves like NeoCloud — size positions accordingly and expect volatility around data releases. Not financial advice.

Open on X

@moninvestorMay 8, 2026 · 9:17 AM

According to Grok, the 5 stocks with realistic 10X upside in the next year: 1. $JOBY - eVTOL air taxis nearing certification/commercial launch. 2. $CRSP - CRISPR gene-editing therapies with multiple late-stage catalysts. 3. $GTBIF - Cannabis if U.S. federal reform accelerates. 4. $IREN - Bitcoin mining + AI data center power play. 5. $SOFI - Fintech scaling into full digital banking. Interesting names. All have potential but I think it will take several years to 10x.

Open on X

@kaizen_investorMar 21, 2026 · 2:07 PM

6. $CRSP - A gene editing company - Industry: Biopharma - Stars: 5 - Fair value: $106 - Economic Moat: None - Equity Style: Mid Growth - Uncertainty: Very High - Potential Upside: 130% https://t.co/wFhTWdQMKm

Open on X

@adamfeuersteinMar 11, 2026 · 11:09 AM

@BioStocks Add $CRSP $550M convertible notes. Upsized from $350M

Open on X

@midascabalJan 19, 2026 · 12:39 AM

Looking into gene editing stocks like $PRME $CRSP and $BEAM. Which one do you believe is the best and why?

Open on X

@investmentguru_Jan 14, 2026 · 1:54 AM

Key themes to watch: •Early Detection ( $GH, $EXAS ) : AI-driven diagnostics and liquid biopsy remain one of the fastest paths to real-world impact and revenue scalability. •Robotics & Automation ( $ISRG, $RBOT ) : Surgical automation is a long-duration growth story as hospitals push for precision, efficiency, and cost control. •Multi-omics & Genomics ( $TXG, $ILMN, $CRSP, $BEAM $TEM ) : AI + sequencing is accelerating target discovery, personalization, and next-gen therapies. •Virtual Care & Monitoring ( $TDOC, $HIMS ) : AI-driven engagement, triage, and personalization continue to reshape patient access and care delivery. •AI Drug Discovery ( $RXRX, $SDGR, $ABCL ) : Platform-based models remain volatile short term but offer asymmetric upside as pipelines mature. •Infrastructure & Enablers ( $VEEV, $DOCS, $GEHC ) : The “picks and shovels” of AI healthcare adoption.

Open on X

@adamfeuersteinDec 6, 2025 · 9:09 PM

Hello! If you can break away from college football for a moment... #ASH25 Day One recap $SNDX Revuforj frontline AML results $VRTX $CRSP Casgevy in young kids Star Therapeutics - Von Willebrand disease Stand up for Science buttons and a brief STAT event recap https://t.co/in6RTsvyip via @statnews

Open on X

@adamfeuersteinNov 8, 2025 · 3:04 PM

CRISPR-based treatment cuts cholesterol and triglycerides in early study https://t.co/Y03kJtJZYN via @matthewherper $CRSP $NTLA $LLY

Open on X

@ftr_investorsOct 22, 2025 · 3:09 PM

Open on X

$CRSP

$CRSP

About this stock

Frequently asked

Related stocks